JP2019535295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535295A5 JP2019535295A5 JP2019528462A JP2019528462A JP2019535295A5 JP 2019535295 A5 JP2019535295 A5 JP 2019535295A5 JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019535295 A5 JP2019535295 A5 JP 2019535295A5
- Authority
- JP
- Japan
- Prior art keywords
- probe
- base length
- nucleotides
- ligated product
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 230000002759 chromosomal effect Effects 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 108091008146 restriction endonucleases Proteins 0.000 claims 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001973 epigenetic effect Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101000846284 Homo sapiens Pre-mRNA 3'-end-processing factor FIP1 Proteins 0.000 claims 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100031755 Pre-mRNA 3'-end-processing factor FIP1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 238000011895 specific detection Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022183117A JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| US62/428,893 | 2016-12-01 | ||
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183117A Division JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535295A JP2019535295A (ja) | 2019-12-12 |
| JP2019535295A5 true JP2019535295A5 (enExample) | 2021-01-14 |
Family
ID=60702831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528462A Pending JP2019535295A (ja) | 2016-12-01 | 2017-11-30 | がんの診断における後成的染色体相互作用の応用 |
| JP2022183117A Active JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183117A Active JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP4357463A3 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7617029B2 (ja) * | 2019-05-08 | 2025-01-17 | オックスフォード バイオダイナミックス ピーエルシー | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2614118C (en) | 2005-07-04 | 2013-11-26 | Erasmus University Medical Center | 4c |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| EP2121977B1 (en) * | 2007-01-11 | 2017-06-21 | Erasmus University Medical Center | Circular chromosome conformation capture (4c) |
| CA2609172A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Utah Research Foundation | Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| WO2010036323A1 (en) * | 2008-09-25 | 2010-04-01 | University Of Massachusetts Medical School | Method of identifing interactions between genomic loci |
| EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
| CN103180459B (zh) * | 2010-07-09 | 2016-10-19 | 赛尔冉迪思股份有限公司 | 3-d目的基因组区域的测序策略 |
| WO2012116317A2 (en) * | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| EP2710146A2 (en) * | 2011-05-18 | 2014-03-26 | Life Technologies Corporation | Chromosome conformation analysis |
| CA2880896C (en) * | 2012-06-26 | 2021-11-16 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| EP3314018A1 (en) | 2015-06-24 | 2018-05-02 | Oxford Biodynamics Limited | Detection processes using sites of chromosome interaction |
| US11339442B2 (en) | 2015-12-14 | 2022-05-24 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active